Concentra Reports Strong Preliminary Q4 Visit Growth, Reaffirms FY25 Guidance, and Repurchases Shares
summarizeSummary
Concentra Group Holdings Parent, Inc. reported strong preliminary Q4 2025 operational metrics, including significant year-over-year visit growth, reaffirmed its full-year 2025 guidance, and executed a notable share repurchase program.
check_boxKey Events
-
Preliminary Q4 2025 Operational Metrics
The company reported strong preliminary, unaudited Q4 2025 operational metrics, with total company workers' compensation visits up 9.1% and employer services visits up 9.4% year-over-year.
-
FY 2025 Guidance Reaffirmed
Concentra reaffirmed its full-year 2025 guidance, projecting revenue between $2.145 billion and $2.160 billion, and Adjusted EBITDA between $425 million and $430 million.
-
Significant Share Repurchase
The company repurchased approximately 1.1 million shares in Q4 2025, representing a capital allocation decision valued at roughly $22 million based on current stock price.
-
J.P. Morgan Healthcare Conference Presentation
These preliminary results and guidance will be presented at the J.P. Morgan Healthcare Conference on January 14, 2026.
auto_awesomeAnalysis
This 8-K filing provides an early, positive look into Concentra's Q4 and full-year 2025 performance ahead of its presentation at the J.P. Morgan Healthcare Conference. The reported preliminary operational metrics, particularly the strong year-over-year visit growth across both workers' compensation and employer services, indicate robust business momentum. Reaffirming the full-year 2025 revenue and Adjusted EBITDA guidance suggests management confidence in achieving its financial targets. Furthermore, the repurchase of approximately 1.1 million shares in Q4 2025 demonstrates a commitment to returning capital to shareholders and signals management's belief in the company's intrinsic value. Investors should view these updates as a strong indication of continued operational strength and financial stability. The upcoming flash results and 2026 guidance in late January will provide further clarity on the company's trajectory.
At the time of this filing, CON was trading at $19.96 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $18.55 to $24.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.